Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $130M (up 59.3% year over year) with net income of $15M.
Q2 2026 key financials · XBRL
- Revenue
- $130M
- +59.3% YoY · +23.2% QoQ
- Net income
- $15M
- +194.5% YoY · +232.9% QoQ
- Operating margin
- 12.7%
- EPS (diluted)
- $0.12
- +200.0% YoY · +233.3% QoQ
Source: XBRL data from the Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 10-Q on SEC EDGAR. USD.
Arcutis Biotherapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $129.9M, up 59% YoY from $81.5M
- Best performer: ZORYVE foam $67.4M, up 72% YoY
- ZORYVE cream 0.05% revenue $2.9M, launched October 2025
- Research and development expense $20.4M, up 5% YoY; SG&A up 19%
- Cash, restricted cash, and marketable securities $238.9M; $100.0M debt outstanding; sufficient for at least 12 months
Risk Factors
- No risk-factors section provided; supplied text begins with Item 2 and contains no comparison with the 10-K
- CEO trading-plan change: terminated June 4, 2026 plan covering up to 325,000 shares
- CEO replacement plan: potential exercise and sale of up to 325,000 options through August 31, 2027
- Chief Legal Officer plan: potential exercise and sale of up to 40,000 options plus 45,792 shares through September 1, 2027
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcutis Biotherapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.